This suggests that MUC3A and MUC 13 may become immunotherapeutic targets for ccRCC, and further studies on the biological mechanisms involved in the progression of ccRCC by MUC3A and MUC 13 are needed, that can be promising strategies in the treatment of ccRCC patients. This evidence concerns the gene MUC3A and nonpapillary renal cell carcinoma.